Navigation Links
Verenium Launches Second Enzyme Product for Oilfield Services
Date:1/5/2012

SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the introduction of VEREFLOW™ alpha-amylase, a unique enzyme for the removal of filter cake in drilling operations.  This high performance enzyme effectively removes filter cake that acts as a barrier to hydrocarbon flow on the face of the wellbore, the hole drilled in the creation of a well.  Effective over a wide temperature and pH range and with a safer environmental footprint compared to traditional chemicals often used in the process, VEREFLOW™ alpha-amylase provides the oilfield services industry greater operational flexibility. 

 

"We are pleased to be expanding our offering in the oilfield services market to offer another high-performance enzyme product with a superior environmental profile – a key advantage to operators in this industry," said James Levine, President and Chief Executive Officer at Verenium. 

 

Verenium estimates the addressable global market for VEREFLOW™ alpha-amylase in the United States to be approximately $20 million annually. The Company began marketing and selling VEREFLOW™ alpha-amylase in the first quarter of 2012 and manufactures the enzyme under its agreement with Fermic S.A. de C.V in Mexico City.

 

 

About VEREFLOW™ Alpha-Amylase

VEREFLOW™ alpha-amylase is a high performance enzyme designed to break down filter-cake created by water-based mud containing starch and other polymers used in drilling operations. VEREFLOW™ alpha-amylase has been shown to be effective over an exceptionally wide temperature and pH range providing greater operational flexibility without a loss in productivity through the normal variability of downhole conditions during wellbore clean up.  VEREFLOW™ alpha-amylase, compared to traditional chemicals used in the key drilling process of reservoir cleanup, is safe for both operators and the environment.

 

About Verenium

Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, ability to obtain additional capital to support its planned operations and financial obligations, dependence on patents and proprietary rights,  and protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

 

Contacts:

Kelly Lindenboom                              

Vice President, Corporate Communications

858-431-8580

kelly.lindenboom@verenium.com

Sarah Carmody

Manager, Corporate Communications
858-431-8581

sarah.carmody@verenium.com


'/>"/>
SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium to Host Analyst and Investor Day
2. Verenium Reports Financial Results for the First Quarter Ended March 31, 2011
3. Verenium Corporation to Announce First Quarter 2011 Financial Results
4. Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
5. Verenium Announces Changes in Senior Management
6. Verenium Announces 2010 Business Update and Outlook for 2011
7. Successful Diabetes Product Launches Balance Digital & Traditional Public Relations Tools
8. Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
9. theVisualMD Launches a Revolutionary New Visual Path to Wellness
10. Mylan Launches First Generic Version of Teveten® Tablets
11. Doximity Launches ExpertFinder to Match Clinical Need with Clinical Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology:
(Date:6/23/2016)... Angeles, CA (PRWEB) , ... June 23, 2016 , ... ... conducted that may expose a possible link between head and neck cancer in individuals ... participating in the study were evaluated based on whether they had gum disease, brushed ...
(Date:6/23/2016)... Beaumont, TX (PRWEB) , ... June 23, 2016 , ... ... family and business clients throughout Jasper County and the surrounding region, is initiating a ... The charity drive will raise funds earmarked for a scholarship fund that will be ...
(Date:6/23/2016)... ... June 23, 2016 , ... Virginia Beach resident Sean Kelly suffered from depression ... water to find peace and set out to accomplish a personal mission: a solo ... the internet. He came across the story of another special operations veteran, Josh Collins, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the 20th International Congress of Parkinson’s Disease and Movement Disorders. This special session ... experts, highlighting the relevance, novelty, and quality of both clinical and basic research ...
(Date:6/23/2016)... ... ... The U.S. Supreme Court decision on immigration has significant consequences for Social Security ... (TSCL) . “President Obama’s executive actions on immigration would have provided long - ... country illegally, even though the newly - issued green cards are only temporary,” says ...
Breaking Medicine News(10 mins):